XENT - Intersect ENT, Inc.
15.90 0.00 (0.00%)
After hours: 4:36PM EDT
| Previous Close | 16.18 |
| Open | 16.65 |
| Bid | 15.91 x 800 |
| Ask | 15.92 x 1400 |
| Day's Range | 15.78 - 16.10 |
| 52 Week Range | 15.76 - 35.87 |
| Volume | 152,781 |
| Avg. Volume | 372,635 |
| Market Cap | 500.418M |
| Beta (3Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.43 |
- Thomson Reuters StreetEvents
Edited Transcript of XENT earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Intersect Ent Inc Earnings Call
- Zacks
Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss
Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.
Motley FoolIntersect ENT (XENT) Q2 2019 Earnings Call Transcript
XENT earnings call for the period ending June 30, 2019.
- Motley Fool
Why Intersect ENT Is Down Big Today
Shares dropped after the company reported second-quarter results that missed the mark, and cut guidance.
- Zacks
Intersect ENT (XENT) Reports Q2 Loss, Lags Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -5.88% and -1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Intersect ENT Reports Second Quarter 2019 Results
CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1
- Business Wire
Intersect ENT Announces FDA Approval of New PROPEL Mini Straight Delivery System
Intersect ENT®, Inc. (XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for a new Straight Delivery System (SDS) for use to place its PROPEL® Mini steroid releasing sinus implant in the ethmoid sinus. PROPEL Mini helps maintain the sinus opening while delivering mometasone furoate directly where it is needed, improving outcomes of frontal (behind the forehead) and ethmoid (behind the bridge of the nose) sinus surgery. The new SDS is designed to help physicians achieve precise and easy delivery of the PROPEL Mini implant to the ethmoid sinus.
- Zacks
Earnings Preview: Intersect ENT (XENT) Q2 Earnings Expected to Decline
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Intersect ENT to Report Second Quarter 2019 Financial Results
Intersect ENT, Inc. (XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET. To access the conference call via the internet, go to the "Investor Relations" page of the company's website at www.intersectENT.com.
- ACCESSWIRE
CLASS ACTION UPDATE for LYFT, XENT and RMED: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 15, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 15, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. ("Intersect" or "the Company") (XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and May 6, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before July 15, 2019.
- ACCESSWIRE
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XENT, HL and RMED
CEDARHURST, NY / ACCESSWIRE / July 15, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- ACCESSWIRE
FINAL DEADLINE - Intersect ENT, Inc. (XENT) Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: July 15, 2019
NEW YORK, NY / ACCESSWIRE / July 15, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intersect ENT, Inc. (“Intersect ENT” or the “Company”) ...
- GlobeNewswire
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. (“Intersect” or “the Company”) (NASDAQ: XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Intersect failed to maintain the necessary force of reimbursement representatives to ensure physicians’ access to SINUVA, its sinus implant.
- ACCESSWIRE
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 14, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. ("Intersect" or "the Company") (XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and May 6, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before July 15, 2019.
- ACCESSWIRE
SHAREHOLDER ALERT: XENT AOS PYX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / July 14, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have ...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intersect ENT, Inc. - XENT
Pomerantz LLP is investigating claims on behalf of investors of Intersect ENT, Inc. (“Intersect” or the “Company”) (XENT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intersect and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- GlobeNewswire
FINAL DEADLINE NOTICE: Kaskela Law LLC Reminds Intersect ENT, Inc. Investors of Important July 15, 2019 Deadline in Shareholder Class Action Lawsuit – XENT
PHILADELPHIA, July 13, 2019 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Intersect ENT, Inc. (“Intersect” or the “Company”).
- ACCESSWIRE
FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 13, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. ("Intersect" or "the Company") (XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and May 6, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before July 15, 2019.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EQBK, XENT and EROS
NEW YORK, NY / ACCESSWIRE / July 12, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
- ACCESSWIRE
TOP RANKED ROSEN LAW FIRM, FINAL DEADLINE: Reminds Intersect ENT, Inc. Investors of the JULY 15 Deadline in Securities Class Action - XENT
NEW YORK, NY / ACCESSWIRE / July 12, 2019 / Rosen Law Firm, a global investor rights law firm, reminds Intersect ENT, Inc. (NASDAQ: XENT) from August 1, 2018 through May 6, 2019, inclusive (the "Class ...
- GlobeNewswire
SHAREHOLDER ALERT - Intersect ENT, Inc. (XENT) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: July 15, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intersect ENT, Inc. (“Intersect ENT” or the “Company”) (XENT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Intersect ENT securities between August 1, 2018 and May 6, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- ACCESSWIRE
JULY 15 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. ("Intersect" or "the Company") (XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and May 6, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before July 15, 2019.
- ACCESSWIRE
SHAREHOLDER ALERT: EQBK XENT EROS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / July 12, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have ...
- ACCESSWIRE
Intersect ENT, Inc. (XENT) Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: July 15, 2019
NEW YORK, NY / ACCESSWIRE / July 12, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intersect ENT, Inc. (“Intersect ENT” or the “Company”) (XENT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Intersect ENT securities between August 1, 2018 and May 6, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
